PPARG and osteosarcoma: The inhibitory effects of the RARb antagonist LE135, PPARg antagonist T0070907, LXR agonist T0901317 and Rev-Erba agonist SR9011 were all abolished in the corresponding NR-knockout cells (Fig. 2M–P), indicating that the NR modulators specifically target the corresponding NRs to inhibit osteosarcoma cell growth.